Longeveron Inc. (NASDAQ:LGVN) Short Interest Update

Longeveron Inc. (NASDAQ:LGVN) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totaling 979,704 shares, a decrease of 26.6% from the December 15th total of 1,334,145 shares. Based on an average daily trading volume, of 372,571 shares, the days-to-cover ratio is currently 2.6 days. Approximately 5.2% of the shares of the company are sold short. Approximately 5.2% of the shares of the company are sold short. Based on an average daily trading volume, of 372,571 shares, the days-to-cover ratio is currently 2.6 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Longeveron in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Longeveron has a consensus rating of “Hold” and an average target price of $6.50.

Longeveron Price Performance

LGVN stock traded down $0.01 during midday trading on Friday, reaching $0.55. The company had a trading volume of 75,911 shares, compared to its average volume of 229,422. Longeveron has a 1-year low of $0.49 and a 1-year high of $1.92. The stock has a 50 day moving average price of $0.60 and a 200-day moving average price of $0.87. The company has a market capitalization of $11.77 million, a price-to-earnings ratio of -0.52 and a beta of 0.21.

Longeveron (NASDAQ:LGVN) last released its earnings results on Tuesday, November 4th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.13). Longeveron had a negative net margin of 1,485.25% and a negative return on equity of 138.44%. The firm had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.29 million. As a group, research analysts anticipate that Longeveron will post -3.69 earnings per share for the current year.

Hedge Funds Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd acquired a new position in shares of Longeveron Inc. (NASDAQ:LGVN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron as of its most recent SEC filing. Institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.